Amyotrophic lateral sclerosis (ALS) is a degenerative disorder of motor neurons that leads to progressive muscle wasting and weakness, with a typical survival time of three to five years from onset…
Biosimilars│Emerging Biosimilars│Inflectra │U.S. Wave 1 is the first installment of a three-wave, syndicated report series, tracking physician perception and uptake of Pfizer/Celltrion’s…
This three-wave syndicated report series tracks the introduction of Darzalex, a human anti-CD38 MAb, and Empliciti, a humanized anti-SLAMF7 MAb. The FDA approved these agents in November 2015 for…
Following the introduction of the anti-VEGF therapies over a decade ago, the wet AMDmarket has been dominated by three therapies—Roche/Genentech/Novartis’s Lucentis, approved for wet AMD,…
There are limited treatment options for patients with advanced/metastatic, triple-negative breast cancer because commonly used treatments in other breast cancer segments (i.e., hormonal therapies…
With its launch in August 2016, Zinbryta became the 14thdisease-modifying therapy (DMT) approved to treat relapsing forms of multiple sclerosis (MS) in the United States. The monoclonal antibody…
Immune (idiopathic) thrombocytopenic purpura (ITP) is a hematological autoimmune disorder characterized by low platelet count in the blood, which may lead to easy bruising and bleeding. ITP has an…
Fewer than ten new brands have launched in the highly generic and crowded Parkinson’s disease (PD) therapy market during the past two decades, but PD’s large and growing elderly population and…
Abstract: Hepatocellular carcinoma is the most common form of liver cancer. It is the seventh-most-common type of cancer worldwide and the third-most-common cause of cancer death worldwide. Most…
The rheumatoid arthritis (RA) therapy market has matured to the point that TNF-α inhibitors have become firmly established as first-line biological agents, leaving non-TNF-α inhibitor agents to…
The HIV therapy market is very dynamic. Over the last decade, many effective antiretroviral (ARV) therapies have been introduced, prompting changes in treatment guidelines and clinical…
The hepatitis C virus (HCV) therapy market has been marked by tremendous growth and has undergone a rapid evolution of the treatment landscape with the launch of novel direct-acting antivirals (…
Gram-negative infections (GNIs) account for a large portion of hospital-treated infections (HTIs), which represent a high-value segment of the antibacterial market given the severity of these…
Amyloidosis refers to the disruption and damage to organs and tissues due to deposits of abnormal, insoluble amyloid fibrils, which are formed by the accumulation of misfolded proteins. Amyloid…
